Chronic Refractory Pouch Dysfunction
|
|
- Samson Walker
- 6 years ago
- Views:
Transcription
1 Chronic Refractory Pouch Dysfunction Anatomy of Pelvic Pouches Afferent limb (neo-ti) Tip of J J S W Inlet Efferent limb Bo Shen, MD The Ed and Joey Story Endowed Chair Professor of Medicine The Cleveland Clinic Foundation Cleveland, Ohio Indications for Colectomy in UC Outlet/cuff/ anal transitional Efferent limb zone Frequency of Chronic with Different Pouch Configurations 00% 80% 60% 40% 20% 3.0% 8.3% 0.0% 0% J pouch S pouch K pouch N = 25 N = 45 N = 36 Mukewar S, Shen B, DDW 202 J, K Pouches vs. Ileostomy Brooke Ileostomy Kock Pouch Pelvic J Pouch Disorders of the Ileal Pouch Surgical/ Mechanical Inflammatory/ Infectious Functional Neoplastic Systemic/ Metabolic - Irritable - Pouch/ATZ - Anemia -Anastomotic leak - pouch syn. Neoplasia - Bone loss - Pelvic sepsis - Cuffitis -Anismus - Lymphoma - Vit D def. - Sinus - Crohn s dis. Poor Squamous - Renal stone - Fistula - Small cell cancer - Vit B2 def. - Strictures bowel bacterial compliance - Pseudo- Celiac dis. -Afferent limb syn. overgrowth obstruction/ - Efferent limb syn. - Inflammatory megapouch - Infecundity polyps - Hypersensitive - Sexual suture lines dysfunction - Pouchalgia - Portal vein thrombi - Prolapse - Twist/volvulus Updated from Shen B, et al. AJG 2005;00; Foreign body
2 Afferent Limb Syndrome Owl s Eyes and Pouch Dysfunction Shen B, Remzi FH, Fazio VW. CGH 2008;6:45-58 Endoscopic Predictors of Pouch Failure Factor HR (95% CI) p Crohn s pouch 2.7 (.2, 6.3) 0.08 Surgical complications 4.4 (.7,.2) Post-operative biologics 5.3 (2.5,.2) < abnormalities of Owls beak 3.6 (.5, 8.7) Cuff endoscopy score.5 (.3,.7) <0.00 Efferent Limb Syndrome 7 cm N = 426 Shen B, Remzi FH, Fazio VW. CGH 2008;6: cm Alder K, Shen B. IBDJ 203 S pouch (no owls eyes) Twisted Pouch 2
3 Endoscopic Clues for Etiology of? Kock Pouch Hemorrhagic Fever-CMV Tight Nipple Valve Stricture C. Diff NSAID Ischemia Chronic Natural History of Ischemia Surgery-associated anatomic comp Refractory Relapsing Disease Activity Episodic Nl pouch or FAP pouch Months Metronidazole Pathogenetic Model of Why not in FAP Pouches? Abnormal Immune Response Therapeutic Target Genetic Susceptibility Mechanical factors (e.g. ischemia) Alteration commensal bacteria (dysbiosis) Pathogens Therapeutic Target Therapeutic Target Luminal factors (e.g.nsaids) Navaneethan U & Shen B. AJG 200;05:5-64 Cipro Rifaximin Tinidazole Antifungals FMT? Risk Factors for Extensive UC Backwash ileitis Primary sclerosing cholangitis P-ANCA IL-ra, NOD2 polymorphisms NOD2 gene polymorphisms Precolectomy thrombocytosis Fazio VW, et al. Ann Surg995 Schmidt CM, et al. Ann Surg 998 Non-smoker Lohmuller JL, et al. Ann Surg 990 Fleshner P, et al. Gut2003 NSAIDs Achkar JP, et al. CGH 2005 Arthralgia Shen B, et al AJG 2005 Meier CB, et al. IBDJ 2005 Surgical techniques?? Shen B, et al, CGH 2006 Fleshner P, et al. CGH2007 Koltun W, et al. DCR 20 Tyler A, et al. Gut 202 3
4 Management of Conventional RCT of Antibiotic Therapy in Cipro or Metronidazole x 2 wks Median in PDAI score N Type of pouchitis Agent Madden994 3 Chronic pouchitis Metro 400 mg TID vs. placebo 7 N/A Shen Acute pouchitis Cipro g/d vs.n Metro. 20 mg/kg/d 4 Cipro -6.7 Metro -5.9 Isaacs Acute or Chronic pouchitis Rifaximin.2 g/ d vs. placebo in study group Authors Days Responded Not Responded Metronidazole or Cipro x 2 more wks Infrequent Relapse Frequent Relapse Antx -responsive Antibiotics prn Responded Antx -dependent Probiotic or Antibiotic Carbon Microsphere? Lactulose? Not Responded Antx-refractory Cipro + Metronidazole or Rifaximin or Tinidazole x 4 wks Not Responded 5-ASA/steroids/ Immunomodulators/Biologics? Open-labeled Trials of Antibiotics in N Type of pouchitis Drugs Duration (days) Med ian in PDAI Madiba acute p. antx dependent p. chr antx refractory p, Metro 200 mg TID 30 Clin response in 77% acute p. Shen Antibiotic dependent p. Rifaximin 200 mg/day 90-3 Shen Chronic antx refractory p. Cipro g/day + Tinidazole 5/mg/kg/d 28-7 Gionchetti Chronic antx refractory p. Cipro g/d +Rifaximin 2 g/ d 5-7 Abdelrazaq Chronic antx refractory p. Cipro gm/d + Rifaximin 2g/d 4-2 Kornbluth Chronic antx refractory p. Rifaximin g/d 2 Clin response in 8% Mimura Refractory acute p. Metro mg/d + Cipro gm/d 28-9 Hurst Acute antx responsive p. Metro. 750 mg/d or Cipro g/d 7 Clin response in 94% Study Probiotics in Primary or Secondary Prophylaxis of Authors Year N Design Gionchetti/Gastro RCT Relapse 9 mo : 5% vs 00% Gionchetti /Gastro RCT 2 (0%) in study group; 8 (40%) in placebo group had pouchitis at 2 mo Mimura/Gut RCT Relapse 9 mo: 6% vs 85% Shen/APT Openlabeled McLaughlin/DDW Openlabeled Outcome On VSL3 at 8 mo: 9% Idiopathic (dysbiosis-associated) Rationale for Antibiotic/Probiotic Therapy in Idiopathic Shoot blindly Target: dysbiosis alteration in quality/quanlity of commensal bacteria Consequences Bacterial resistance Opportunistic infection (C. difficile) Remission 3% 4
5 Fecal Coliform Culture in Number Patients Resistant Sensitive + Treat E. Coli 6 Klebsiella Ciprofloxacin (00%) Co-amoxiclav (40%) Cefixime (60%) Trimethoprim (73%) Co-amoxiclav (53%) Trimethoprim (3%) Colistin (33%) Coliform, not classified 2 Pseudomonas Morganella Range of C. difficile 4-wk treatment with sensitive antibiotics (N =5): - Median 24-hr st ool f requency: Median PDAI symptom score: 4 0 McLaughlin SD. CGH 2009;7:545 Secondary (with identifiable etiology/triggering factors) Innocent? superimposed infectant? or original culprit? Campylobacter Pathogen-associated pouchitis NSAID-induced pouchitis Ischemic pouchitis Immune-mediated pouchitis Fever, malaise, dehydration Rx: Erythromycin Shen B, et al. AJG 200;05:472-3 Clostridium difficile Infection in Pouch Authors Year N Prevalence Outcome Mann/ DCR Recovered Shen/ DDS Recovered Shen/ CGH % Risk factors: Male (OR=5.0) Shen/NRGH Fatal 96 % (PCR for toxin B) Refractory/Recurrence to vancomycin Li/IBDJ 203 C. diff pouchitis CMV He XS, Shen B. IBDJ 200 C. diff enteritis 5
6 Candida: Part of Mucosal Associated Bacteria/Fungi Navaneethan U & Shen B. AJG 200;05:5-64 Imaging Features of Ischemic Ischemic Ischemic Clues: Male Difficult pouch in operative note (the issue of reach ) Obese or excessive weight gain (>5% of baseline) Abdominal surgery (hernia repair, mesh) Portal vein thrombi Antibiotic refractory Crohn s Disease Shen B, et al. IBDJ 200 Implication of the Identification of Ischemic Different from ischemic colitis or mesenteric ischemia Necrosis/bowel infarction hardly occurs Doppler or angiogram often negative Potential surgical treatment Lysis of adhesion Pouch revision or redo pouch (J J; J K) Shen B, et al, Inflamm Bowel Dis 200;6: Ischemic Lysis of Adhesion in Treatment of Ischemic Shen B, et al, Inflamm Bowel Dis 200;6:
7 Clinical Clues for Immune-mediated + enteritis Chronic antibiotic-refractory pouchitis Concurrent autoimmune disorders Serum autoantibodies -Year Budesonide in PSC-associated /Enteritis Pre- Post- P Afferent limb Endoscopy Score 2.3 ± ± Pouch Endoscopy Score 2.5 ± ± N = 8 Induction: 9mg/day 3 months Maintenance: 3mg/day No impact on LFTs Navaneethan U, et al. JCC 202;6: Enteritis in PSC + UC with or without Colectomy and Ileal Pouch Neo-Terminal Ileum Pouch Inlet Terminal Ileum Ileal Cecal Valve IgG4-associated 29% in refractory pouchitis Serum IgG4 may be normal Current autoimmune disorders are common Budesonide-st line therapy Pouch Colon Navaneethan U, et al. JCC 20;5:570-6 PSC-associated /Enteritis Long segment of distal small bowel disease in addition to diffuse pouchitis Concurrent autoimmune disorders are common (3% vs. 6% in control) Budesonide-st line therapy Autoimmune (GVHD-like) Chronic antibiotic-refractory pouchitis Concurrent autoimmune diseases Serum auto-antibodies Budesonide, small dose immunomodulator Apoptosis Normal Pouch Shen B. IBDJ 20;7: Autoimmune Jiang W, et al. DCR 202;55:
8 Cuffitis: A Residual UC? Ischemic/Collagenous Cuffitis B 2 cm D Shen B, et al. IBDJ 200 Cuffitis Diagnosis at the st Visit* N = 20 5ASA/steroidresponsive Cuffitis 5ASA/steroidrefractory Cuffitis 5ASA/steroiddependent Cuffitis N = 40 N = 58 N = 22 Crohn s Disease Refractory Cuffitis Surgical Complications (Fistula, Sinus) N = 9 N = 25 N = 4 Pouch Excision/Revision/ Diversion Pouch Excision/Revision /Diversion Pouch Excision/Revision / Diversion N=7 N=5 N=4 Lysis Adhesion in Treatment of Refractory Cuffitis *Mean duration of IBD before colectomy = 7.4 ± 7.2 yrs Wu B, et al. IBDJ 203 Mean duration of the pouch = 7. ± 5.3 yrs Refractory Cuffitis-A Sign of CD? Chronic Inflammation Low-grade Dysplasia High-grade Dysplasia Invasive Cancer 3 Years 8
9 Pouch Cancer/Dysplasia: Is Surveillance Endoscopy Indicated & Adequate? Cox Model for Risk Factors for Pouch Neoplasia 7 months Adjusted HR (95%CI) P Male gender.6 ( ) Age at pouch.0 ( ) Duration of UC.0 ( ) PSC 0.4 ( ) Chronic pouchitis 0.69 ( ) Extensive colitis.53 ( ) ( ) < ( ) ( ) Colectomy for cancer Colectomy for dysplasia Mucosectomy Kariv R, et al. Gastroenterology 200;39: Classification of Crohn s Disease of Pouch Inflammatory Pouch Neoplasia: Cleveland Clinic Experience N=3203 Fibrostenotic Fistulizing Crohn s Disease in Patients with IPAA Cumulative Frequency % Yu 2000 Duetsch N = 59 N = 272 Fazio 2003 Neilly 999 N = 86 N = 7 Gemlo 992 N = 96 Keighley 2000 N = 222 Peyregne 999 N = 54 adenocarcinoma ; lymphoma ; SCC 3; dysplasia 23 Kariv R, et al. Gastroenterology 200;39:
10 Pouch Failure in Patients with Crohn s Disease 00 C umulat iv e Frequenc y % Diagnostic Algorithm for Crohn s Pouch Pouch Endoscopy & Biopsy Iatrogenic Complications, (fistula, leaks) / Ileitis 5-ASA Failure Cuffitis Diagnostic/ Therapeutic EUA 0 N = 67 Peyregne 999 Duetsch 99 Sagar 996 Gemlo 992 Tulchinsky 2003 Keighley 2000 Neilly 999 N = 79 N = 9 N = 37 N = 3 N = 3 N = 23 N=8 Trial of Biologics Shen B. IBDJ 2009;5: Open-Labeled Trial Infliximab in Fistulizing Crohn s Disease of the Pouch 00 Diagnosis/Management of Pouch Disorders Clinical Presentations Consistent with Antibiotic-refractory Chronic Median f/u = 22 months N = 26 Pouchoscopy + Biopsy 80 % of Cases Crohn s Disease Confirmed Review Colectomy Specimen, Contrasted Enema CTE MRI, EGD, serology? Fazio 995 Crohn s Disease Suspected Antibiotic Failure Diffuse /Enteritis 62% Segmental /Ileitis or Distal ± Cuffitis Stricture/ Fistula Sinus/Obstruction/ Structural Disease % 23% Labs (microbiology, ANA, LFTs, IgG4, celiac/anti- microsomal abs) Histology (apoptosis, IgG4, hematoidin) Histology, Abdominal Imaging ± Exam under Anesthesia 5% 20 Pathogen-induced 0 Complete Response Partial Response No Response Pouch Failure Induction Therapy Colombel JF, et al. AJG 2005 Adalimumab for Crohn s Disease of Pouch Factor Short term Long term Clinical response (N=48) None (%) 4(29.2) 22(45.8) Partial (%) Complete (%) 0(20.8) 24(50.0) 0(20.8) 6(33.3) Clinical response inflammatory fibrostenotic disease (N=23) or None (%) Partial (%) 7(30.4) 6(26.) 2(52.2) 4(7.4) 0(43.5) 7(30.4) None (%) 7(28.0) 0(40.0) Partial (%) 4(6.0) 6(24.0) Complete (%) Clinical response in fistulizing disease (N=25) Complete (%) Mucosal healing (%) Pouch failure (%) 4(56.0) 9(36.0) 20(4.7) NA 3(27.) 9(8.8) C.difficile CMV Immune-mediated PSC associated IgG4associated Ischemic Crohn s Disease Surgical Complications Autoimmune Pouchopathy Shen B. CGH 203 Summary A number of patients with chronic refractory pouch dysfunction in fact have surgery-associated mechanical or structural disorders is disease spectrum with ranging etiopathogenetic pathways, disease course, and prognosis De novo Crohn s disease can occur in pouch patients with a preoperative diagnosis of UC Emerging C. diffificle infection is challenging Cuffitis can in patients with restorative colectomy with ileal pouches Cancer risk persists after colectomy Most pouch cancer occurs at the cuff area Li Y, et al. IBDJ 202;8:
11 Thank You!
Pouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board
Pouchitis and Cuffitis A bloody mess Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Ileal-pouch anal anastomosis https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinicalbriefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis
More informationChallenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence
Challenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence Sharon Dudley-Brown, PHD, FNP-BC, FAAN Assistant Professor Johns Hopkins University Baltimore, MD sdudley2@jhmi.edu Disclosures
More informationMaintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice
Aliment Pharmacol Ther 2005; 22: 721 728. doi: 10.1111/j.1365-2036.2005.02642.x Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice B. SHEN*, A. BRZEZINSKI*,
More informationReview. Risks and benefits of ileal pouch anal anastomosis for ulcerative colitis. Udayakumar Navaneethan 1, Preethi GK Venkatesh 1 & Bo Shen 1
Review Risks and benefits of ileal pouch anal anastomosis for ulcerative colitis Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the surgical treatment of choice for patients with
More informationClinical Approach to Diseases of Ileal Pouch-Anal Anastomosis
American Journal of Gastroenterology ISSN 0002-9270 C 2005 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2005.00278.x Published by Blackwell Publishing CLINICAL REVIEW Clinical Approach to
More informationCase Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
Gastroenterology Research and Practice Volume 2010, Article ID 860394, 4 pages doi:10.1155/2010/860394 Case Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent Jessica
More informationSurgical Management of IBD. Val Jefford Grand Rounds October 14, 2003
Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two
More informationRisk Factors for Diseases of Ileal Pouch Anal Anastomosis After Restorative Proctocolectomy for Ulcerative Colitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:81 89 Risk Factors for Diseases of Ileal Pouch Anal Anastomosis After Restorative Proctocolectomy for Ulcerative Colitis BO SHEN,* VICTOR W. FAZIO, FEZA
More informationSURGICAL MANAGEMENT OF ULCERATIVE COLITIS
SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management
More informationAzienda Ospedaliera S. Camillo Forlanini. Unità Operativa di Gastroenterologia. Moscow June Cosimo Prantera
/ Azienda Ospedaliera S. Camillo Forlanini Unità Operativa di Gastroenterologia Moscow June 2006 Cosimo Prantera ANTIBIOTICS AND BACTERIAL SPECIES Metronidazole Bacteroides - Clostridia Ciprofloxacin Escherichia
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationIleoanal Pouch Solves the Problem
Ileoanal Pouch Solves the Problem Bruce D George Department of Surgery John Radcliffe Hospital, Falk Symposium 2-3 May 2008 Ileoanal Pouch Solves the Problem? Sometimes Not always Key Issues in Pouch Surgery
More informationInflammatory Bowel Disease When is diarrhea not just diarrhea?
Inflammatory Bowel Disease When is diarrhea not just diarrhea? Jackie Kazik, MA, PA C CME Resources CAPA Annual Conference, 2011 Inflammatory Bowel Disease Objectives Discuss what is known about the pathophysiology
More informationSecond European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations
CROHNS-00649; No of Pages 33 Journal of Crohn's and Colitis (2012) xx, xxx xxx Available online at www.sciencedirect.com SPECIAL ARTICLE Second European evidence-based consensus on the diagnosis and management
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationIndex. Surg Clin N Am 87 (2007) Note: Page numbers of article titles are in boldface type.
Surg Clin N Am 87 (2007) 787 796 Index Note: Page numbers of article titles are in boldface type. A Abscesses in anorectal Crohn s disease, 622 intra-abdominal, in Crohn s disease, 590 591 perirectal,
More informationIleal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationPatho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology
Patho Basic Chronic Inflammatory Bowel Diseases Jürg Vosbeck Pathology General Group of chronic relapsing diseases with chronic bloody or watery diarrhea Usually ulcerative colitis (UC) or Crohn s disease
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationMy Child Has Inflammatory Bowel Disease : Why? What now? What s next?
My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationCLINICAL MANAGEMENT. Clinical Management of Pouchitis. Clinical Case. Background
GASTROENTEROLOGY 2004;127:1809 1814 CLINICAL MANAGEMENT Loren Laine, M.D. Clinical Management Editor University of Southern California Los Angeles, California Clinical Management of Pouchitis WILLIAM J.
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationInflammatory Bowel Disease: Updates and Controversies CASE #1 CASE #1 8/6/2015. What is the most likely diagnosis?
Inflammatory Bowel Disease: Updates and Controversies Tehttp://192.185.93.102/~paulkeij/wpcontent/uploads/2013/07/collaboration.jpgxt August 7, 2015 Meagan M Costedio, MD; Colorectal Surgery; Cleveland
More informationDiarrhoea for the Acute Physician
Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationCRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1
Colorectal Cancer and in IBD: A Case-Based Approach Fernando Velayos MD MPH Associate Director of Translational Research University of California, San Francisco Center for Crohn s s and Colitis CRC and
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationAvailable online at ScienceDirect
Journal of Crohn's and Colitis (2014) 8, 1227 1236 Available online at www.sciencedirect.com ScienceDirect Comparison of long-term outcomes of S and J pouches and continent ileostomies in ulcerative colitis
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationSurgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma?
17 th Panhellenic IBD Congress Thessaloniki May 2018 Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma? Janindra Warusavitarne Consultant Colorectal Surgeon, St
More informationSurgery for Ulcerative Colitis 11/14/10. Colectomy for Ulcerative Colitis: What your patient should know. Surgery for Ulcerative Colitis
Colectomy for Ulcerative Colitis: What your patient should know Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Surgery for Ulcerative
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationAnus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon dx.doi.org/10.23922/jarc.2016-008 http://journal-arc.jp ORIGINAL RESEARCH ARTICLE Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab
More informationCase Presentations #2 Saturday November 13, Case #1 HPI 11/14/10. Uma Mahadevan-Velayos MD. Complicated Crohn s Pregnancy
Case Presentations #2 Saturday November 13, 2010 Uma Mahadevan-Velayos MD Case #1 Complicated Crohn s Pregnancy HPI 34 yo F with Crohn s disease presents to office 18 weeks pregnant, moved back to SF from
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationPitfalls in the Diagnosis of Inflammatory Bowel Disease
Pitfalls in the Diagnosis of Inflammatory Bowel Disease Robert H Riddell MD Mt Sinai Hospital Toronto Prof of Lab. Medicine and Pathobiology University of Toronto Atypical gross / endoscopic distribution
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationSurgery for Inflammatory Bowel Disease
Surgery for Inflammatory Bowel Disease Emily Steinhagen, MD Assistant Professor Department of Surgery, Division of Colorectal Surgery University Hospitals Cleveland Medical Center Common Questions Why
More informationThe role of antibiotics and probiotics in pouchitis
INVITED REVIEW Annals of Gastroenterology (2012) 25, 1-6 The role of antibiotics and probiotics in pouchitis Paolo Gionchetti a, Andrea Calafiore a, Donatella Riso a, Giuseppina Liguori a, Carlo Calabrese
More informationColostomy & Ileostomy
Colostomy & Ileostomy Indications, problems and preference By Waleed Omar Professor of Colorectal surgery, Mansoura University. Disclosure I have no disclosures. Presentation outline Stoma: Definition
More informationHomayoon Akbari, MD, PhD
Recent Advances in IBD Surgery Homayoon M. Akbari, MD, PhD, FRCS(C), FACS Associate Professor of Surgery Virginia Commonwealth University Crohn s disease first described as a surgical condition, with the
More informationSurgical Management of IBD in the Age of Biologics
Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationInflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital
Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents
More informationInflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura
Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Sourasky Medical Center Tel Aviv, Israel IBD- clinical features
More informationPrimary sclerosing cholangitis (PSC) is a chronic, cholestatic
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:540 546 Progressive Primary Sclerosing Cholangitis Requiring Liver Transplantation Is Associated With Reduced Need for Colectomy in Patients With Ulcerative
More informationEpidemiology / Morbidity
Perianal Crohn s Disease: Current Treatment Approach David A Schwartz, MD Director, Inflammatory Bowel Disease Center Vanderbilt University Medical Center Epidemiology / Morbidity Hellers et al, Gut 1980
More informationIndex. Note: Page numbers of article title are in boldface type.
Index Note: Page numbers of article title are in boldface type. A Abscess(es) in Crohn s disease, 168 169 IPAA and, 110 114 as unexpected finding in colorectal surgery, 46 Adhesion(s) trocars-related laparoscopy
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationMicroscopic Colitis. Darrell S. Pardi, MD Inflammatory Bowel Disease Clinic Mayo Clinic
Microscopic Colitis Darrell S. Pardi, MD Inflammatory Bowel Disease Clinic Mayo Clinic Research Disclosure Astra Zeneca, P&G, Salix* Consulting Salix* *This program is supported by Salix. Neither Mayo
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationSurgery in Inflammatory Bowel Disease. Rajesh Gupta MS, MCh Surgical Gastroenterology Division Dept of General Surgery PGIMER, Chandigarh
Surgery in Inflammatory Bowel Disease Rajesh Gupta MS, MCh Surgical Gastroenterology Division Dept of General Surgery PGIMER, Chandigarh 1 Ulcerative colitis (UC) Ulcerative colitis (UC) characterized
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationThe role of Surgery and Stomas in IBD
The role of Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationPrevention, Diagnosis, and Treatment of Complications of the IPAA for Ulcerative Colitis
RESIDENT S CORNER Prevention, Diagnosis, and Treatment of Complications of the IPAA for Ulcerative Colitis Stefan D. Holubar, M.D., M.S. Department of Colon & Rectal Surgery, Digestive Disease and Surgery
More informationRestorative proctocolectomy with ileal pouch anal anastomosis. Clostridium difficile Infection in Patients With Ileal Pouch Anal Anastomosis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:782 788 Clostridium difficile Infection in Patients With Ileal Pouch Anal Anastomosis BO SHEN,* ZHI DONG JIANG, VICTOR W. FAZIO, FEZA H. REMZI, LILIANA RODRIGUEZ,
More informationAnti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
More informationUlcerative Colitis: State of the Art 2006
Ulcerative Colitis: State of the Art David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Improving Management of Ulcerative Colitis (UC) Better classification/diagnostic
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationDiagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases
Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationCrohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationSurgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?
Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences between
More informationDiagnostics and disease monitoring in IBD: State of the art 2011
Diagnostics and disease monitoring in IBD: State of the art 2011 David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University of Chicago Medical Center The
More informationDisease behavior in adult patients- are there predictors for stricture or fistula formation?
Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More information... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment.
Definition Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. " Epidemiology Humans represent the main reservoir of Clostridium difficile, which is not part of the
More informationWelcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group.
Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online. Last week s material consisted of an overview of inflammatory bowel diseases (IBD), specifically Crohn s disease and ulcerative
More informationWhat is Crohn's disease?
What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationMichael D. Kreines, M.D.
Michael D. Kreines, M.D. Gastroenterology Section Chief Medical Director, IBD Program The Christ Hospital of Cincinnati Ohio GI and Liver Institute www.ohiogi.com This Year s Story How to figure out how
More informationRestorative Proctocolectomy For Ulcerative Colitis IN
590540SJS0010.1177/1457496915590540Restorative proctocolectomyi. Helavirta, H. Huhtala, M. Hyöty, P. Collin, P. Aitola research-article2015 Original article Restorative Proctocolectomy For Ulcerative Colitis
More information